No Data
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
JMP Securities analyst Jonathan Wolleben maintains $Spruce Biosciences(SPRB.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 4
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
HC Wainwright & Co. Reiterates Neutral on Spruce Biosciences
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating
H.C. Wainwright analyst Ram Selvaraju maintains $Spruce Biosciences(SPRB.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 42.2% and a total average return of 1.6%
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and ScPharmaceuticals (SCPH)